Premium
SSRI‐associated gastrointestinal bleeding
Author(s) -
Lam Y. W. Francis
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30457
Subject(s) - medicine , serotonin , platelet , depression (economics) , serotonin reuptake inhibitor , platelet aggregation , kidney disease , reuptake , pharmacology , receptor , economics , macroeconomics
Patients with chronic kidney disease (CKD) are often prescribed antidepressants, including selective serotonin reuptake inhibitors (SSRIs), for management of depression. The SSRIs have a very favorable safety profile overall but have been associated with bleeding risk as a result of their blocking serotonin uptake in platelets and the resultant inhibition of platelet aggregation.